La cadena de opciones muestra datos clave de las opciones de acciones de Gryphon Digital Mining a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Gryphon Digital Mining..

Gryphon Digital Mining (NASDAQ:GRYP) Bolsa, Cadena de Opciones

Gryphon Digital Mining

Gryphon Digital Mining Inc is a Bitcoin mining company. Gryphon's mission is to create the world's net carbon-neutral Bitcoin miner. The company will operate a digital asset, mining operation using specialized computers equipped with application-specific integrated circuit (ASIC) chips to solve complex cryptographic algorithms in support of the Bitcoin blockchain in exchange for cryptocurrency rewards. It has vigorously acquired and develop energy assets for AI and high-performance computing (HPC) data center infrastructure. It acquire power assets, and then add electrification, infrastructure and computing power to those assets.

Gryphon Digital Mining, Inc - Common Stock

Gryphon Digital Mining Inc

GRYPHON GOLD CORP by Gryphon Gold Corp.

Gryphon Digital Mining Inc Warrants (17/06/2024)

On May 29, 2025, Shineco, Inc. (the "Company") entered into a securities purchase agreement (the "SPA") with certain non-U.S. investors (the "Purchasers"), pursuant to which the Company agreed to sell, and the Purchasers agreed to purchase, severally and not jointly, an aggregate of 18,000,000 shares of common stock of the Company (the "Shares") at an offering price of $ 0.75 per share (the "Offering"). Each Purchaser has represented that he or she is not a resident of the United States and is not a "U.S. person" as defined in Rule 902(k) of Regulation S under the Securities Act and is not acquiring the Shares for the account or benefit of any U.S. person. The gross proceeds of the Offering are expected to be approximately $13.5 million, before the deduction of customary expenses.
&nbsp;
In reliance on the Purchasers' representations to the Company, the Shares to be issued in the Offering are not subject to the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Regulation S promulgated thereunder. Neither this Current Report on Form 8-K, nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Shares described herein.
&nbsp;
The SPA contains customary representations and warranties of the Company and the Purchasers, indemnification obligations of the Purchasers, and other obligations and rights of the parties. Additionally, the closing of the Offering is conditioned upon the consummation of certain matters by the Company, including, if required by the Nasdaq Listing Rules, submitting a Listing of Additional Shares Notification Form to Nasdaq and obtaining the approval by Nasdaq of the transactions contemplated thereby. Subject to the satisfaction of the closing conditions, the Offering is expected to close on or about June 16, 2025.

News

Offerings

SISI

Shineco To Raise $13.5M Through Sale Of 18M Common Shares At $0.75 Each To Non-U.S. Investors

Management

UBER

Uber Technologies Appoints Andrew "Mac" Macdonald As President & Chief Operating Officer, Effective Immediately

Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) reported financial results for the fourth quarter of fiscal 2025 after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/06/b45733917/credo-technology-group-holding-ltd-reports-fourth-quarter-and-fiscal-year-2025-financial-results">of the report</a>.
Q4 Earnings: Credo Technology Group reported fourth-quarter revenue of $170.03 million, beating analyst <a href="http://benzinga.com/quote/crdo/earnings">estimates</a> of $162.96 million. The connectivity solutions company reported fourth-quarter adjusted earnings of 35 cents per share, beating analyst estimates of 28 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue in the quarter was up 179.7% year-over-year and up 25.9% sequentially. The company reported adjusted gross margin of 67.4%. Credo Technology Group ended the period with $431.3 million in cash and short-term investments.
&#8220;The Company&#8217;s results were fueled by surging demand for our innovative, reliable and energy-efficient high-performance connectivity solutions. We continue to see growing demand for our solutions across hyperscaler customers to power advanced AI services, a trend we believe will persist for the foreseeable future,&#8221; said Bill Brennan, president and CEO of Credo Technology Group.
Outlook: Credo Technology Group expects first-quarter revenue in the range of $185 million to $195 million versus estimates of $167.83 million. The company anticipates an adjusted gross margin between 64% and 66% in the first quarter.
Credo&#8217;s management team will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET.
CRDO Price Action: <a href="http://benzinga.com/quote/crdo">Credo Technology shares</a> were up 15.26% in Monday&#8217;s after-hours session, trading at $72.21 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45728618/stocks-stall-commodities-rocket-as-trade-geopolitical-tensions-resume-whats-driving-market-monday">Stocks Stall, Commodities Rocket As Trade, Geopolitical Tensions Resume: What&#8217;s Driving Markets Monday?</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/bluestork">bluestork</a>/Shutterstock.

Earnings

Movers

Trading Ideas

CRDO

Credo Technology Group Q4 Earnings: Revenue Beat, EPS Beat, Strong Guidance, Company Says Results Fueled By 'Surging Demand'

WIIM

Credo Technology Group Holding shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 sales guidance above estimates.

Strategy&#x2122; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>, STRK, STRF))) today announced that, subject to market and other conditions, it intends to conduct an initial public offering registered under the Securities Act of 1933, as amended (the "Securities Act"), of 2,500,000 shares of Strategy's 10.00% Series A Perpetual Stride Preferred Stock (the "STRD Stock").
Strategy intends to use the net proceeds from the offering for general corporate purposes, including the acquisition of bitcoin and for working capital.
Dividends on shares of the STRD Stock will not be mandatory. Holders of the STRD Stock will be entitled to receive non-cumulative dividends at a rate per annum equal to 10.00% on the stated amount (as defined below) thereof, out of funds legally available for their payment to the extent paid in cash, only when, as, and if declared by our board of directors or any duly authorized committee thereof. If declared, regular dividends on the STRD Stock will be payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year, beginning on September 30, 2025. Since regular dividends are not cumulative, Strategy will not have any obligation to pay any regular dividend for any regular dividend period unless Strategy declares such regular dividend prior to the regular dividend payment date for such regular dividend period. No dividend, interest or other amount will accumulate or accrue on any unpaid regular dividends, regardless of whether regular dividends are declared for any future regular dividend period. Declared regular dividends on the STRD Stock will be payable solely in cash in the manner, and subject to the provisions, described in the prospectus supplement for the offering.
Strategy will have the right, at its election, to redeem all, but not less than all, of the STRD Stock, at any time, for cash if the total number of shares of all STRD Stock then outstanding is less than 25% of the total number of shares of STRD Stock originally issued in the offering and in any future offering, taken together. In addition, Strategy will have the right to redeem all, but not less than all, of the STRD Stock if certain tax events occur. The redemption price for any STRD Stock to be redeemed will be a cash amount equal to the liquidation preference of the STRD Stock to be redeemed as of the business day before the date on which Strategy sends the related redemption notice, plus declared and unpaid regular dividends, if any, that will have accrued to, but excluding, the redemption date (and without payment of any undeclared regular dividends).
If an event that constitutes a "fundamental change" under the certificate of designations governing the STRD Stock occurs, then, holders of the STRD Stock will have the right to require Strategy to repurchase some or all of their shares of STRD Stock at a cash repurchase price equal to the stated amount of the STRD Stock to be repurchased, plus declared and unpaid regular dividends, if any, that will have accrued to, but excluding the fundamental change repurchase date (and without payment of any undeclared regular dividends).
The liquidation preference of the STRD Stock will initially be $100 per share (the "stated amount"). Effective immediately after the close of business on each business day after the initial issue date (and, if applicable, during the course of a business day on which any sale transaction to be settled by the issuance of STRD Stock is executed, from the exact time of the first such sale transaction during such business day until the close of business of such business day), the liquidation preference per share will be adjusted to be the greatest of (i) the stated amount per share of STRD Stock; (ii) in the case of any business day with respect to which Strategy has, on such business day or any business day during the ten trading day period preceding such business day, executed any sale transaction to be settled by the issuance of STRD Stock, an amount equal to the last reported sale price per share of STRD Stock on the trading day immediately before such business day; and (iii) the arithmetic average of the last reported sale prices per share of STRD Stock for each trading day of the ten consecutive trading days (or, if applicable, the lesser number of trading days as have elapsed during the period from, and including, the initial issue date to, but excluding, such business day) immediately preceding such business day.

IPOs

MSTR

Strategy Announces Plans For IPO Of 2.5M Shares Of 10% Series A Perpetual Stride Preferred Stock (STRD) To Fund Bitcoin Acquisitions And Corporate Operations

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1870404/000121390025050055/ea0244195-8k_cero.htm" title="https://www.sec.gov/ix?doc=/Archives/edgar/data/1870404/000121390025050055/ea0244195-8k_cero.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1870404/000121390025050055/ea0244195-8k_cero.htm</a>

CERO

CERo Therapeutics Appoints Chris Ehrlich As CEO

At the annual meeting of stockholders of Amaze Holdings, Inc., a Nevada corporation (the "Company"), to be held on June 12, 2025 (the "Annual Meeting"), the Company's stockholders will vote to approve, among other things, a proposal to authorize a reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock"), at a ratio in the range of 1-for-10 and 1-for-50, with such ratio and implementation and timing of the reverse stock split to be determined in the discretion of the Company's Board of Directors (the "Reverse Stock Split Proposal").
&nbsp;
On June 2, 2025, the Company's Board of Directors determined to effect a 1-for-23 reverse stock split of the Company's issued and outstanding Common Stock effective at 5:00 p.m. Eastern time on June 12, 2025 (the "Effective Time"), subject to stockholder approval of the Reverse Stock Split Proposal at the Annual Meeting.
&nbsp;
Upon stockholder approval of the Reverse Stock Split Proposal at the Annual Meeting, immediately following the conclusion of the Annual Meeting on June 12, 2025, the Company will file a certificate of amendment to its Articles of Incorporation to effect the 1-for-23 reverse stock split at the Effective Time. The Company's Common Stock is expected to begin trading on a reverse stock split adjusted basis on the NYSE American at market open on June 13, 2025.
&nbsp;
The reverse stock split is primarily intended to increase the Company's per share market price of its Common Stock to meet the $3.00 per share minimum bid price requirement of the NYSE American Company Guide. The Company's Common Stock will continue to trade on the NYSE American under the trading symbol "AMZE," but will trade under the following new CUSIP number: 35804X 200.

Stock Split

AMZE

Amaze Holdings To Implement 1-For-23 Reverse Stock Split, Aiming To Regain NYSE American Compliance; Stock To Begin Trading On Split-Adjusted Basis June 13, 2025

On May 28, 2025 (the "Closing Date"), our Avis Budget Rental Car Funding (AESOP) LLC subsidiary ("ABRCF") issued $736.5 million of asset-backed securities with a maturity of three years and five years, respectively, comprised of $199.0 million aggregate principal amount of Series 2025-1 4.80%, Class A notes, $29.75 million aggregate principal amount of Series 2025-1 5.24%, Class B notes, $21.25 million aggregate principal amount of Series 2025-1 5.87%, Class C notes and $33.29 million aggregate principal amount of Series 2025-1 7.48%, Class D notes, as well as $318.4 million aggregate principal amount of Series 2025-2 5.12%, Class A notes, $47.6 million aggregate principal amount of Series 2025-2 5.51%, Class B notes, $34.0 million aggregate principal amount of Series 2025-2 6.24%, Class C notes and $53.26 million aggregate principal amount of Series 2025-2 7.84%, Class D notes. The Class D notes were retained by ABRCF and may be sold on a future date. ABRCF also issued $15.6 million aggregate principal amount of Series 2025-1 9.424%, Class R notes and $25.0 million aggregate principal amount of Series 2025-2 9.795%, Class R notes, each of which are subordinated to the Class A notes, the Class B notes, the Class C notes and the Class D notes of the respective Series, and which were issued to comply with applicable U.S. risk retention rules. The Class R notes are held by our AESOP Leasing L.P. subsidiary. The notes were issued under the Series 2025-1 Supplement, dated as of the Closing Date, between ABRCF and The Bank of New York Mellon Trust Company, N.A., as trustee and Series 2025-1 Agent (the "Series 2025-1 Supplement"), to the Second Amended and Restated Base Indenture, dated as of June 3, 2004 (as amended, the "Base Indenture") and the Series 2025-2 Supplement, dated as of the Closing Date, between ABRCF and The Bank of New York Mellon Trust Company, N.A., as trustee and Series 2025-2 Agent (the "Series 2025-2 Supplement"), to the Base Indenture, respectively.

Financing

Avis Budget Rental Car Funding (AESOP) Issues $736.5M In Asset-Backed Securities Across Two Series With Maturities Of 3 And 5 Years

Earnings Misses

NCNA

NuCana Q1 EPADS $(0.75)

BSII

Black Spade Acquisition II To Voluntarily Delist From Nasdaq Upon Consummation Of Pending Business Combination With The Generation Essentials Group

Donaldson Appoints Richard Lewis Chief Operating Officer, Effective August 1, 2025

Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 10 years by 2.12% on an annualized basis producing an average annual return of 13.13%. Currently, Blackstone has a market capitalization of $107.39 billion. 
Buying $100 In BX: If an investor had bought $100 of BX stock 10 years ago, it would be worth $337.69 today based on a price of $138.92 for BX at the time of writing.
<h3>Blackstone's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748895316_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Both Leading Proxy Advisory Firms Recommend Shareholders Vote AGAINST Chairman George Mayes, Jr., Director Javier Polit and Director Laurie Tucker
Glass Lewis Confirms That These Three Directors Are Unlikely to be "Procedurally Accretive" to the Ongoing Strategic Review
Ancora Holdings Group, LLC (together with its affiliates, "Ancora" or "we"), a significant shareholder of Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) ("Forward Air" or the "Company"), today announced that a second independent proxy advisory firm, Glass, Lewis &amp; Co. ("Glass Lewis"), has joined Institutional Shareholder Services Inc. ("ISS"), in recommending that Forward Air shareholders vote AGAINST the reelection of three members of the Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders: (1.) George S. Mayes, Jr., (2.) Javier Polit and (3.) Laurie A. Tucker.
In its report, Glass Lewis states the following regarding the case for removing these directors from the Board:1
<ul>
<li>"Are legacy directors who served during the questionable pursuit, fumbled execution and to-date maladroit implementation of the Omni deal credibly positioned to oversee Forward's current assessment of value-maximizing opportunities? We believe the answer is a firm no."</li>
<li>"[I]nvestors do not have clear and compelling cause to believe Messrs. Mayes and Polit and Ms. Tucker are likely to be procedurally accretive and indeed have ample cause to conclude they have not been effective in preserving and enhancing shareholder value, particularly in the context of transformative transactions."</li>
</ul>

FWRD

Both ISS And Glass Lewis Urge Forward Air Shareholders To Vote Against Chairman George Mayes Jr., Directors Javier Polit And Laurie Tucker, Citing Poor Oversight Of Omni Deal And Lack Of Value-Enhancing Contributions

BYFC

Broadway Financial Announces Nasdaq Noncompliance Notification

– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate –
– The trial evaluated three doses of onvansertib in combination with paclitaxel, and objective responses were observed only at the highest dose of onvansertib –
– The combination was well-tolerated and demonstrated a safe and manageable toxicity profile –
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced positive data from an investigator-initiated Phase 1b clinical trial evaluating onvansertib in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC) at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30-June 3, 2025, in Chicago, Illinois.

CRDF

Cardiff Oncology Presents Data From Investigator-Initiated Phase 1b Clinical Trial Evaluating Onvansertib In Combination With Paclitaxel In Patients With mTNBC At 2025 ASCO Annual Meeting

ENSG

The Ensign Group Acquires Nursing Facility In California; Financial Terms Not Disclosed

Dividends

EPRT

Essential Properties Realty Trust Increases Quarterly Dividend From $0.295 To $0.30/Share

First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months&nbsp;for atezolizumab alone from the point of randomization
First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance
Results presented at the ASCO 2025 Annual Meeting and simultaneously published in The Lancet
Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data
For U.S. media and investors only
DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced positive results from the Phase 3 IMforte study of Zepzelca&#xAE; (lurbinectedin) in combination with atezolizumab (Tecentriq&#xAE;) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, etoposide and atezolizumab. The study met both primary endpoints, demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to atezolizumab alone.
IMforte is the first global Phase 3 trial to demonstrate clinically meaningful PFS and OS benefits in the first-line maintenance setting for ES-SCLC and supports maintenance therapy with Zepzelca&nbsp;plus atezolizumab as a new standard of care for patients. The data were presented today in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and published simultaneously in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439716-1&amp;h=26984983&amp;u=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736(25)01011-6%2Ffulltext&amp;a=The+Lancet">The Lancet</a>. Data from the trial served as the basis for the supplemental New Drug Application (sNDA) submission to the U.S. Food and Drug Administration&nbsp;(FDA).
Following induction therapy with carboplatin, etoposide and atezolizumab, patients who did not have disease progression were randomized to receive Zepzelca plus atezolizumab or atezolizumab alone. From the point of randomization, the median PFS was 5.4 months for the Zepzelca plus atezolizumab combination versus 2.1 months for atezolizumab alone (stratified HR = 0.54, 95% CI: 0.43–0.67; p &lt; 0.0001), and median OS was 13.2 months versus 10.6 months (stratified hazard ratio [HR] = 0.73; 95% CI: 0.57–0.95; p = 0.0174). The combination reduced the risk of disease progression or death by 46% and the risk of death by 27% compared to atezolizumab alone. The Zepzelca plus atezolizumab combination had no new or unexpected safety signals.

Biotech

General

JAZZ

Jazz Pharmaceuticals Announces Phase 3 IMforte Trial Results Showing Zepzelca Plus Atezolizumab First-Line Maintenance Therapy Reduces Disease Progression Risk By 46% And Extends Median Overall Survival To 13.2 Months In ES-SCLC; Data Presented At ASCO 2025 And Published In The Lancet, Supporting New Standard Of Care And FDA sNDA Submission

Overall pan-cancer sensitivity of 94% and specificity of 100%, with analytical detection down to 1 PPM
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54263860&amp;newsitemid=20250602831213&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=7205b90051b2da6a2abf789e99afd34b">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assay, which was presented today, June 2nd, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The study analyzed the performance of Signatera Genome in a cohort of 392 patients (&gt; 2,600 plasma samples) across five different tumor types (breast cancer, non-small cell lung cancer, melanoma, renal cell carcinoma, and colorectal cancer). Key results included:
<ul>
<li>Excellent pan-cancer performance: Signatera Genome demonstrated overall longitudinal sensitivity of 94% and specificity of 100% across 5 cancer types. Longitudinal sensitivity was 100% in lung cancer and renal cancer, and post-surgical landmark sensitivity was over 70% in both lung cancer and breast cancer.</li>
<li>Ultrasensitive detection: In the surveillance setting, nearly 50% of Signatera-positive cases were detected in the ultra-sensitive range (≤100 parts per million).</li>
<li>Highly predictive of long-term outcomes: In the pancancer cohort, patients who tested Signatera-negative had excellent prognosis, with 100% distant relapse-free survival (DRFS) at 12 months and 99% at 24 months. In contrast, Signatera-positive patients faced a markedly higher risk of recurrence, with DRFS dropping to 41% at 12 months and just 14% at 24 months.</li>
<li>Extended lead times: Signatera Genome detected recurrence 3 months earlier, on average, compared to the Signatera Exome assay.</li>
<li>Demonstrates Signatera's potential to identify which patients may benefit from adjuvant therapy: Among Signatera-positive patients, those who received adjuvant therapy had significantly improved outcomes, with a 12-month DRFS of 83% compared to 49% for those who did not receive therapy. For Signatera-negative patients, there was no meaningful benefit from adjuvant therapy with a 12-month DRFS of 93% (treated) vs. 98% (observation).</li>
</ul>

NTRA

Natera Presents Results From Large-Scale Pan-Cancer Study Of Signatera Genome Assay At 2025 ASCO Annual Meeting

Empowering enterprises across industries to build and deploy secure, compliant AI agents and applications with Snowflake Postgres, powered by Crunchy Data's enterprise-grade PostgreSQL
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.snowflake.com%2F&amp;esheet=54263223&amp;newsitemid=20250602455530&amp;lan=en-US&amp;anchor=Snowflake&amp;index=1&amp;md5=ba422637d7f8c26f397a956c82baaa6a">Snowflake</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), the AI Data Cloud company, today announced at its annual user conference, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.snowflake.com%2Fen%2Fsummit%2F&amp;esheet=54263223&amp;newsitemid=20250602455530&amp;lan=en-US&amp;anchor=Snowflake+Summit+2025&amp;index=2&amp;md5=2df932361745e54fc8138426404cb066">Snowflake Summit 2025</a>, its intent to acquire Crunchy Data, a leading provider of trusted open source Postgres technology and products. This acquisition will bring Snowflake Postgres, the AI-ready, enterprise-grade and developer-friendly PostgreSQL database to the AI Data Cloud, enabling developers with the full power of Postgres while providing the uncompromising governance, security and operational standards essential for building and running mission-critical AI applications.

SNOW

Snowflake To Acquire Crunchy Data; Terms Undisclosed

Press Releases

Gryphon Digital Mining Expands Bitcoin Mining Fleet by 22% and Evaluates Creation of a Bitcoin Strategic Reserve Designed to Strengthen Balance Sheet

Gryphon Digital Mining Announces Strategic Bitcoin Reserve Initiative

Gryphon Digital Concludes Legal Dispute with Sphere 3D Corp.

Gryphon Digital Mining to Host Fourth Quarter and FY 2024 Earnings Conference Call

Gryphon Digital Mining Reports Fourth Quarter and FY 2024 Financial Results

Hut 8 Subsidiary American Bitcoin Announces Go-Public Transaction

American Bitcoin Announces Go-Public Transaction through Strategic Merger with Nasdaq-Listed Entity

Gryphon Digital Mining Announces Merger with American Bitcoin

Stocks Under $5 to Watch: KDLY, PRSO, NXTT, GRYP, YHC Lead Headlines with Bitcoin, AI, and Semiconductor Catalysts

Fintech

Small Cap

Dominari Holding's Strategic Interest in Bitcoin Mining Set to Go Public

DOMH

GRYP

KDLY

NXTT

PRSO

TSX:HUT

AudioEye

Cheetah Mobile Inc. American Depositary Shares, each representing fifty (50) Class A Ordinary Shares

Comments

Gryphon Digital Mining

Gryphon Digital Mining (GRYP) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL